| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.71B | 13.97B | 16.08B | 23.38B | 23.20B | 13.11B |
| Gross Profit | 5.59B | 4.88B | 3.50B | 8.39B | 8.57B | 5.39B |
| EBITDA | 2.55B | 2.65B | 3.53B | 6.24B | 6.36B | 3.79B |
| Net Income | 1.52B | 1.58B | 2.05B | 3.26B | 3.68B | 2.38B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 22.52B | 21.46B | 19.63B | 18.75B | 13.10B |
| Cash, Cash Equivalents and Short-Term Investments | 3.50B | 3.50B | 3.31B | 3.09B | 515.37M | 173.23M |
| Total Debt | 0.00 | 110.27M | 196.97M | 575.74M | 1.01B | 1.27B |
| Total Liabilities | -20.18B | 2.34B | 2.53B | 2.65B | 5.60B | 4.00B |
| Stockholders Equity | 20.18B | 18.45B | 17.22B | 15.54B | 12.50B | 8.94B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 874.82M | 704.14M | 2.62B | 842.07M | -221.07M |
| Operating Cash Flow | 0.00 | 2.73B | 3.34B | 3.82B | 2.32B | 1.10B |
| Investing Cash Flow | 0.00 | -1.61B | -1.64B | -1.86B | -1.47B | -615.89M |
| Financing Cash Flow | 0.00 | -447.73M | -749.66M | -812.33M | -565.13M | -374.51M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₹32.92B | 24.08 | ― | 0.08% | 15.47% | -1.72% | |
66 Neutral | ₹122.24B | 78.69 | ― | 0.06% | 69.32% | 113.55% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
61 Neutral | ₹45.54B | 29.91 | ― | 0.95% | -10.76% | -27.70% | |
61 Neutral | ₹93.53B | 51.34 | ― | 0.60% | 3.95% | 8.28% | |
51 Neutral | ₹38.85B | 115.48 | ― | 0.09% | 8.44% | -35.59% | |
47 Neutral | ₹8.41B | 138.91 | ― | 1.14% | -22.10% | -85.56% |
Balaji Amines Limited has announced a change in the schedule for its investor conference call to discuss the Q2 and H1FY26 financial results. Originally planned for 4:00 PM IST, the call has been rescheduled to 12:30 PM IST on the same day, November 12, 2025. This adjustment reflects the company’s proactive approach to engaging with stakeholders and ensuring timely communication of its financial performance.
Balaji Amines Limited has issued a clarification regarding a defamatory article published in the Economic Times, which falsely accused the company of producing pharmaceutical-grade chemicals without a license. The company refutes these claims, stating that they only manufacture technical and food grade Propylene Glycol and have not supplied any pharmaceutical-grade products. Balaji Amines emphasizes their commitment to transparency and compliance with regulations, noting that there is no ongoing investigation by Indian authorities as suggested in the article.
Balaji Amines Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ending September 30, 2025. This certificate confirms that the securities received for dematerialization have been processed, with the depositories’ names updated in the company’s records within the required timeframe, ensuring compliance with regulatory standards.